Trial Profile
A Phase 2, Randomized, Observer-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide
- Indications Typhoid
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 12 Oct 2012 New source identified and integrated (extension trial: EudraCT2011-001448-31).
- 12 Oct 2012 New source identified and integrated (extension trial: EudraCT2011-001448-31).
- 09 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Extension trial: NCT01438996).